anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cell differentiation agent II (CDA-II) exhibits potent anti-proliferative and apoptosis-inducing properties against a variety of cancer cells. However, its mechanism of action in chronic myeloid leukemia (CML) remains unclear.
METHODS: Cell counting Kit 8 (CCK-8) and flow cytometry were used to investigate the effects of CDA-II on the biological characteristics of K562 cells. Gene (mRNA and lncRNA) expression profiles were analyzed by bioinformatics to screen differentially expressed genes and to perform enrichment analysis. The Pearson correlation coefficients of lncRNAs and mRNAs were calculated using gene expression values, and a lncRNA/mRNA co-expression network was constructed. The MCODE and cytoHubba plugins were used to analyze the co-expression network.
RESULTS: The Results, derived from CCK-8 and flow cytometry, indicated that CDA-II exerts dual effects on K562 cells: it inhibits their proliferation and induces apoptosis. From bioinformatics analysis, we identified 316 mRNAs and 32 lncRNAs. These mRNAs were predominantly related to the meiotic cell cycle, DNA methylation, transporter complex and peptidase regulator activity, complement and coagulation cascades, protein digestion and absorption, and cell adhesion molecule signaling pathways. The co-expression network comprised of 163 lncRNA/mRNA interaction pairs. Notably, our analysis results implicated clustered histone gene families and five lncRNAs in the biological effects of CDA-II on K562 cells.
CONCLUSION: This study highlights the hub gene and lncRNA/mRNA co-expression network as crucial elements in the context of CDA-II treatment of CML. This insight not only enriches our understanding of CDA-II's mechanism of action but also might provide valuable clues for subsequent experimental studies of CDA-II, and potentially contribute to the discovery of new therapeutic targets for CML.
Group A received Gong's mobilization, involving 15 mins of electrical stimulation with heat therapy. In a side-lying stance, maintaining 90-degree shoulder abduction, the therapist applied anterior to posterior pressure on the humerus for 10-15 seconds, followed by a 5-second relaxation. Actions included pressing the shoulder joint, extending the articular capsule, and performing shoulder medial rotation. To enhance ROM, oscillation at Maitland's grades 3 and 4 was followed by 7 seconds of prolonged stretching at the grade 4 technique. Routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
The development of a potentially life threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including treatment with paroxetine hydrochloride, but particularly with concomitant use of serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.

The concomitant use of paroxetine hydrochloride with MAOIs intended to treat depression is contraindicated. If concomitant treatment of paroxetine hydrochloride with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

The concomitant use of paroxetine hydrochloride with serotonin precursors (such as tryptophan) is not recommended. Treatment with paroxetine hydrochloride and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
In the current project, the situation applies to individuals with obesity (body mass index (BMI) 35 to 45 kg/m2). In one case the diet is of the type "high-carbohydrate diet" and in the other case "high-fat diet". The idea is that the research subjects should subsist on these diets for the respective 14 days. The energy content of the diet periods must be the same and correspond to the participants' daily needs. Each participant is drawn to one diet for 2 weeks. After a break of at least 3 weeks, the second diet is taken for 2 weeks.
Investigators will enroll 240 patients with STEMI who were admitted to the Chinese PLA General Hospital between Januay 2017 and August 2017. STEMI was defined as typical chest pain lasting 30 min within the previous 12 h, a clear ST-segment elevation of N0.1 mV in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin T. We randomly assign eligible patients in a 1:1 ratio to either 60mg of trimetazidine or oral placebo befor PCI. Trimetazidine group will accept 20mg of trimetazidine for 12 months after PCI and active Comparator will be given placebo for 12 months after PCI.

Primary end point of the study was the area of viable myocardium coming from MR delayed enhancement scan and main cardiovascular events concluding recurrent myocardial infarction, cardiac death, recurrent angina, acute heart failure. Secondary end point of the study was the change of LVEF. All adverse clinical events as well as study end points were monitored and adjudicated by the independent event committee. Each patient was contacted in every week after administration of the contrast, investigated main cardiovascular events (myocardial infarction,acute heart failure and death), and record any adverse events.
Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.

The codeine in Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Regularly evaluate patients with biliary tract disease, including acute pancreatitis for worsening symptoms.

Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding.

The aspirin in Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules, USP can cause GI side effects including stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Physicians should inform patients about the signs and symptoms of GI side effects and what steps to take if they occur.
Inherited metabolic diseases (IMD) are genetic disorders resulting from an enzyme defect and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate metabolism or impaired organelle function. As IMDs can affect the primary sources of energy (glycogen, fatty acids), they can lead to cardiac dysfunction. Although most of IMDs are multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main clinical feature and source of major complications which will determine the prognosis, like heart failure, ventricular arrythmias or even sudden death. Information regarding cardiac manifestations in adult IMDs is currently scarce and little is known about their clinical and radiological characteristics.

A database was created in 2017 including all patients with IMD followed at the Adult Metabolic Clinic in the CHUV. This database was part of a protocol submitted and approved by the Ethics committee (# 2017-02328). The results of this first analysis were published in the Journal of Orphan Rare Diseases. Investigators will use this database to identify all the patients who had cardiac examination. Only patients from the Lausanne University Hospital followed jointly with the Division of Cardiology will be included in the analysis. Electronic and paper patient charts from the Division of Genetic Medicine and Division of Cardiology (Lausanne University Hospital) will be reviewed for type of IMD and cardiac investigations (cardiac ultrasound, multiple resonance Imaging, electrocardiogram). All variables will be entered in an excel database.
The participants will randomly be allocated into two groups: (1) Physical training plus inspiratory muscle training, (2) Physical training

Participants in the physical training plus inspiratory muscle training group will perform inspiratory muscle training and physical training. Inspiratory muscle training will be applied with an electronic device. Physical training will be implemented as balance, mobility, functional strength, endurance exercises. During the hospitalization, the inspiratory muscle training will be carried out twice a day with mild to moderate whereas physical training will be carried out once a day. The physical training group will perform only physical training. Physical training will be implemented as balance, mobility, functional strength, endurance exercises. During the hospitalization, physical training will be carried out once a day. For the safety and feasibility of inspiratory muscle training, data will be collected daily during the hospitalization. For effects of inspiratory muscle training, data will be collected at baseline and hospital discharge.
This arm will receive the intervention. This intervention is access to the SkillTalk for AYA Microskills video library, about 60 minutes in duration. The library includes a curriculum covering skills such as setting boundaries, resolving conflict, and emotional regulation.
Pilot Study - A total of 40 HBOT treatments at 1.5 atmospheres absolute (ATA) for a dive time of 60 minutes, twice a day Monday through Friday. The treatments were separated by an air break of 4 hours on the same day. Measurements of the effectiveness of HBOT in mTBI done before and after HBOT.
Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
PURPOSE:A cancer metastasis inhibitor containing a treated material of protein digestive enzyme as an active constituent. CONSTITUTION:A cancer metastasis inhibitor containing a treated material obtained by incubating a protein digestive enzyme, e.g. pepsine, rennin, trypsin, aminopeptidase, etc., taken out of internal organs of mammals such as pigs. horses, etc., in an aqueous solution under suitable conditions for a given time without particularly adding a substrate thereto and purifying the resultant material by filtration, electrophoresis, chromatographic means, etc., as an active constituent in an amount of 0.1-90%, preferably 1-70%. The inhibitor can be used for various kinds of cancers, e.g. uterine cancer, esophageal cancer, dermal cancer, gastric cancer, etc. The mode of action thereof is not based on direct inhibitory action on agglutination of all the blood platelets, but specific inhibition of agglutination eliciting activity of cancerous cells.
In large part due to the advent of genetic testing, families have recently become a more central focus in cancer prevention. Given the high concordance of health behaviors within families (Kristeller et al., 1996), there is interest in developing family-wide behavior change interventions to reduce cancer risk. A cancer diagnosis represents a "teachable moment," in which a diagnosis may prompt health behavior change. Although this phenomenon has been observed among cancer survivors, it has not been examined among a patient's family members. Several critical questions exist about how families understand and communicate with regard to cancer risk information and what family processes facilitate or impede health behavior change. There is very little existent research in the area of cancer prevention among family members of cancer patients. Results in this area could help us develop interventions for family members who are motivated to make health behavior changes, and to inform and guide others who may not be motivated at the time their family member is diagnosed. Most importantly, the results could also help us intervene with family members of those who have been diagnosed with cancers where genetic and lifestyle components are important in the etiology of the illness, such as lung cancer and melanoma, and thus first-degree family members would benefit from strong messages to adopt healthy lifestyles. The research will rely on qualitative data collection and analysis. We will conduct qualitative interviews with 20 pairs of melanoma patients and one adult son or daughter, and 20 pairs of lung cancer patients and one adult child/sibling/or spouse. More specifically, for each pair of participants (i.e., the patient and his/her family member) we will conduct three interviews: an individual interview with the patient, an individual interview with the family member, and a joint interview where we will talk to the patient and family member at the same time. We will analyze interview data with a qualitative data computer analysis program, and identify themes and conclusions representing the core ideas in our data.
The liver is innervated by primary sensory nerve fibres releasing the neuropeptide calcitonin gene-related peptide (CGRP). Elevated plasma levels of CGRP have been found in patients with liver fibrosis or cirrhosis. We hypothesised that signalling of CGRP and its receptors might regulate liver fibrosis and propose a novel potential target for the treatment. In this study, hepatic expression of CGRP and its receptor component, the receptor activity-modifying protein 1 (RAMP1), was dramatically increased in diseased livers of patients. In a murine liver fibrosis model, deficiency of RAMP1 resulted in attenuated fibrogenesis characterized by less collagen deposition and decreased activity of hepatic stellate cells (HSC). Mechanistically, activity of the TGFβ1 signalling core component Smad2 was severely impaired in the absence of RAMP1, and Yes-associated protein (YAP) activity was found to be diminished in RAMP1-deficient liver parenchyma. In vitro, stimulation of the HSC line LX-2 cells with CGRP induces TGFβ1 production and downstream signalling as well as HSC activation documented by increased α-SMA expression and collagen synthesis. We further demonstrate in LX-2 cells that CGRP promotes YAP activation and its nuclear translocation subsequent to TGFβ1/Smad2 signals. These data support a promotive effect of CGRP signalling in liver fibrosis via stimulation of TGFβ1/Smad2 and YAP activity.
Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
PURPOSE OF THE STUDY: Posterior cortical atrophy is a clinico-radiographical syndrome that presents with higher-order visual dysfunction and is most commonly due to Alzheimer's disease. Understanding factors associated with atypical presentations of Alzheimer's disease, such as posterior cortical atrophy (PCA), holds promise to shape our understanding of AD pathophysiology. Thus, we aimed to compare MRI evidence of lobar microbleeds (LMBs) in posterior cortical atrophy (PCA) syndrome to typical AD (tAD) and to assess and compare MRI evidence of cerebral amyloid angiopathy (CAA) in each group.
FINDINGS: We retrospectively collected clinical and MRI data from participants with PCA (n = 26), identified from an institutional PCA registry, and participants with tAD (n = 46) identified from electronic health records from a single institution. LMBs were identified on susceptibility-weighted imaging (SWI); the Fazekas grade of white matter disease was assessed using FLAIR images, and Boston criteria version 2.0 for cerebral amyloid angiopathy were applied to all data. The proportion of participants with PCA and LMB (7.7%) was lower than for tAD (47.8%) (p = 0.005). The frequency of "probable" CAA was similar in both groups, while "possible" CAA was more frequent in tAD (30.4%) than PCA (0%) (p = 0.001). The Fazekas grades were not different between groups. Lobar microbleeds on SWI were not more common in PCA than in typical AD. Clinicopathological investigations are necessary to confirm these findings. The factors that contribute to the posterior cortical atrophy phenotype are unknown.
Endostar is free supported by Shangdong Simcere Medgene biotech co.,Ltd. Endostar combination with Chemotherapy has been the first line treatment regimen to advanced NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. China NCCN colon or rectal cancer clinical practice guideline recommends Chemotherapy plus angiogenesis inhibitor as the first line treatment scheme. So we design FOLFOX4 plus Endostar to treat advanced colorectal cancer to research the RR and safety. We believe this treatment regimen may be a new approach to the advanced colorectal cancer patients.
The University of Florida operates the SMART program, which will offer four relationship education programs, each targeting a different population: (1) Relationship Smarts PLUS, for high school youth; (2) Before You Tie the Knot, for couples interested in marriage; (3) ELEVATE, for couples, and (4) Smart Steps, for couples in stepfamilies. All programming is offered through the University of Florida's IFAS Extension service in Citrus, Duval, Manatee, Palm Beach, and Santa Rosa counties.

The STREAMS evaluation will test text messaging strategies with couples enrolled in ELEVATE and Smart Steps. It will examine whether text messages informed by behavioral insight theory can improve couples' attendance at relationship skills education group sessions, and if so, which kinds of messages are most effective. ACF staff have noted that among the most common technical assistance requests from HMRE grantees are help with improving participation. Even if relationship skills sessions are offered in a convenient location where adults receive other services and even if programs offer transportation, child care and other assistance to facilitate regular program attendance, achieving consistent participation in these voluntary programs can be challenging. The University of Florida study will help address these challenges by examining whether text messages based on behavioral theories can work as a simple, practical strategy for improving program participation in group sessions. More broadly, the site will also add to the large and growing effort across the federal government to study the use of behavioral interventions or "nudges" to improve social programs.
Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
FIELD: applied microbiology. SUBSTANCE: vaccinal strain A/17/Peking/95/25 (H1N1), which is reassortant, is obtained by cross-breeding of epidemic virus A/Peking/262/95 (H1N1) with cold-adapted temperature-sensitive virus A/Leningrad/134/47/57 (H2N2), which is attenuation donor. The strain is harmless for adults. It actively multiplies in developing chicken embryos at optimal temperature 33-34 C and is characterized by temperature sensitivity and cold adaptability. Reassortant inherits two genes from epidemic virus, which encode surface proteins (gemmagglutinin and neuraminidase). Six genes received from attenuation donor encode non-glycosylated proteins. The strain does non induce immune response in adults during intranasal injection. Biological properties and low degree of immunoreactivity meet Pharmacopoeia requirements for vaccine strains of live influenzal vaccine for intranasal administration for adults. EFFECT: reliably enabled isolation of reassorted vaccinal strains from newly appearing epidemic viruses. 1 tbl
Solutions comprising hypochlorous acid and methods of use are disclosed herein. The disclosed solutions are antiviral and antibacterial. The disclosed solutions may be used to treat and/or prevent a disease state or condition associated with or characterized by acute viral respiratory diseases, such as those caused by coronaviruses. The solutions may be administered by a nebulizer or a metered dose inhaler. The disclosed solutions may also be used to decontaminate surfaces. For example, the disclosed solutions may be used to decontaminate the surfaces of personal protective equipment, such as N95 face mask.
CD47-SIRPα axis is an immunotherapeutic target in tumor therapy. However, current monoclonal antibody targeting CD47-SIRPα axis is associated with on-target off-tumor and antigen sink effects, which significantly limit its potential clinical application. Herein, a biomimetic nano-degrader is developed to inhibit CD47-SIRPα axis in a site-specific manner through SIRPα degradation, and its efficacy in acute myocardial infarction (AMI) is evaluated. The nano-degrader is constructed by hybridizing liposome with red blood cell (RBC) membrane (RLP), which mimics the CD47 density of senescent RBCs and possesses a natural high-affinity binding capability to SIRPα on macrophages without signaling capacity. RLP would bind with SIRPα and induce its lysosomal degradation through receptor-mediated endocytosis. To enhance its tissue specificity, Ly6G antibody conjugation (aRLP) is applied, enabling its attachment to neutrophils and accumulation within inflammatory sites. In the myocardial infarction model, aRLP accumulated in the infarcted myocardium blocks CD47-SIRPα axis and subsequently promoted the efferocytosis of apoptotic cardiomyocytes by macrophage, improved heart repair. This nano-degrader efficiently degraded SIRPα in lysosomes, providing a new strategy for immunotherapy with great clinical transformation potential.
Dental pain is a common reason for patients to visit the dentist. This type of pain is usually easy to diagnose and treat. However, diagnosing and treating other forms of orofacial pain remains complicated. One of the most challenging types of orofacial pain to diagnose and treat is neuropathic orofacial pain: pain resulting from damage to nerve tissue. Recognizing this type of pain in a timely manner can prevent unnecessary invasive dental treatments and disappointment for patients who seek help for this type of pain. There are relatively simple tools for dentists to distinguish neuropathic pain from other types of orofacial pain. The treatment of neuropathic pain is primarily focused on symptom relief through medication.
Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.